Janssen Announces License Agreement With Vertex for development of VX-787, a novel influenza A drug
PRESS RELEASE TITUSVILLE, NJ, July 18, 2014 – Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, More...